Filter Results:
- Full text PDF available (15)
Publication Year
2004
2019
- This year (12)
- Last 5 years (38)
- Last 10 years (47)
Publication Type
Co-author
Journals and Conferences
Learn More
- John C. Byrd, Richard R. Furman, +18 authors Susan M O'Brien
- The New England journal of medicine
- 2013
BACKGROUND
The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling,… (More)
- Richard R. Furman, Jeff P. Sharman, +24 authors Susan O'brien
- The New England journal of medicine
- 2014
BACKGROUND
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies… (More)
- Jonathan W. Friedberg, Jeff P. Sharman, +13 authors Margaret A Shipp
- Blood
- 2010
Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell lymphoma cell… (More)
- Ranjana Hira Advani, Joseph J. Buggy, +12 authors Nathan H Fowler
- Journal of clinical oncology : official journal…
- 2013
PURPOSE
Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We… (More)
- Susan M O'Brien, Richard R. Furman, +19 authors John C. Byrd
- The Lancet. Oncology
- 2014
BACKGROUND
Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its… (More)
- Benjamin D Humphreys, Jeff P. Sharman, +5 authors Colm Christopher Magee
- Cancer
- 2004
BACKGROUND
Gemcitabine-associated thrombotic microangiopathy (TMA) is believed to be very rare, with an estimated incidence rate of 0.015%. Indications for gemcitabine are expanding, and… (More)
- Jonathan Michael Irish, June H Myklebust, +5 authors Ronald Levy
- Proceedings of the National Academy of Sciences…
- 2010
Human tumors contain populations of both cancerous and host immune cells whose malignant signaling interactions may define each patient's disease trajectory. We used multiplexed phospho-flow… (More)
- Steven E. Coutré, Jacqueline C Barrientos, +10 authors Andrew D. Zelenetz
- Leukemia & lymphoma
- 2015
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated… (More)
- Eric D. Jacobsen, Jeff P. Sharman, +9 authors Nancy L. Bartlett
- Blood
- 2015
Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express CD30. This phase 2, open-label study evaluated the efficacy of brentuximab vedotin, an… (More)
- Andres Forero-Torres, Beata Holkova, +9 authors Christopher A. Yasenchak
- Blood
- 2015
Outcomes in older patients with Hodgkin lymphoma (HL) tend to be poor following conventional chemotherapy regimens. Treatment-related toxicity is significant and comorbidities often limit therapeutic… (More)